Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000531413 | SCV000656161 | benign | Ullrich congenital muscular dystrophy 2; Bethlem myopathy 2 | 2023-12-28 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001420886 | SCV001623321 | uncertain significance | not specified | 2021-04-23 | criteria provided, single submitter | clinical testing | Variant summary: COL12A1 c.4613A>G (p.Asn1538Ser) results in a conservative amino acid change located in the Fibronectin type III domain (IPR003961) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00014 in 249232 control chromosomes. To our knowledge, no occurrence of c.4613A>G in individuals affected with Bethlem Myopathy 2 and no experimental evidence demonstrating its impact on protein function have been reported. One other clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, citing the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Gene |
RCV002466535 | SCV002762387 | uncertain significance | not provided | 2022-05-31 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Revvity Omics, |
RCV002466535 | SCV003831221 | uncertain significance | not provided | 2021-05-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004024346 | SCV004928487 | uncertain significance | Inborn genetic diseases | 2023-11-17 | criteria provided, single submitter | clinical testing | The c.4613A>G (p.N1538S) alteration is located in exon 25 (coding exon 24) of the COL12A1 gene. This alteration results from a A to G substitution at nucleotide position 4613, causing the asparagine (N) at amino acid position 1538 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |